Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 1/20 | 0.45 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.44 |
| ▸ | LPL | P06858 | 2/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.38 |
| ▸ | KDR | P35968 | 4/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | SNCA | P37840 | 1/20 | 0.34 |
| ▸ | GSK3A | P49840 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 2/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL407919 | 0.89 | ALPL (0.46) | ALPLAAK1LPLLIPGPDGFRB | |
| SCHEMBL29555798 | 0.89 | ALPL (0.46) | ALPLAAK1LPLLIPGPDGFRB | |
| SCHEMBL6934738 | 0.85 | AAK1 (0.50) | ALPLAAK1LPLLIPGPDGFRB | |
| SCHEMBL23663237 | 0.84 | ALPL (0.45) | ALPLAAK1LPLLIPGPDGFRB | |
| SCHEMBL16175196 | 0.84 | AAK1 (0.46) | ALPLAAK1LPLLIPGPDGFRB | |
| SCHEMBL29504617 | 0.83 | ALPL (0.46) | ALPLAAK1LPLLIPGPDGFRB | |
| SCHEMBL3668559 | 0.83 | ALPL (0.46) | ALPLAAK1LPLLIPGPDGFRB | |
| SCHEMBL20191051 | 0.81 | AAK1 (0.53) | ALPLAAK1LPLLIPGPDGFRB | |
| SCHEMBL29013092 | 0.81 | AAK1 (0.45) | ALPLAAK1LPLLIPGPDGFRB | |
| SCHEMBL26011862 | 0.81 | AAK1 (0.45) | ALPLAAK1LPLLIPGPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612409-B2 | Pyrrolopyrimidines as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION (US) | 2026-04-28 | — | — | US | disclosed |
| US-12258327-B2 | 5-membered heteroaryl-containing aminopyridine compounds as EGFR inhibitors | YUHAN CORPORATION (KR) | 2025-03-25 | — | — | US | disclosed |
| EP-4424311-A2 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | Cystic Fibrosis Foundation (US) | 2024-09-04 | — | — | EP | disclosed |
| EP-3541390-B1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUND (US) | 2024-05-01 | — | — | EP | disclosed |
| US-20240067646-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240067646-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240067646-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. | 2024-02-29 | — | — | US | disclosed |
| US-11753407-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753407-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753407-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| WO-2013119916-A2 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2013-08-15 | — | — | WO | disclosed |
| WO-2013119916-A2 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2013-08-15 | — | — | WO | disclosed |
| WO-2013088404-A1 | Use of inhibitors of the activity or function of PI3K | NOVARTIS AG (CH) | 2013-06-20 | — | — | WO | disclosed |
| EP-2588471-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | Amgen Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| WO-2013057711-A1 | QUINAZOLINE DERIVATIVES AS PI3K MODULATORS | NOVARTIS AG (CH) | 2013-04-25 | — | — | WO | disclosed |
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-04-11 | — | — | US | disclosed |
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-04-11 | — | — | US | disclosed |
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-04-11 | — | — | US | disclosed |
| WO-2012003283-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012003283-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067646-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | ALPL 3534/4885AAK1 3031/4885LPL 1769/4885 |
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | ALPL 3305/4885AAK1 1087/4885LPL 2195/4885 |
| US-12612409-B2 | Pyrrolopyrimidines as CFTR potentiators | CFTR, CLCN2, SLC26A3 | ALPL 2976/4885AAK1 3867/4885LPL 2293/4885 |
| US-12258327-B2 | 5-membered heteroaryl-containing aminopyridine compounds as EGFR inhibitors | EGFR, ERBB2, ERBB4 | ALPL 4809/4885AAK1 473/4885LPL 4764/4885 |
| US-11753407-B2 | Compounds for treating spinal muscular atrophy | SMN1; SMN2, CPT1B, GYS1 | ALPL 4096/4885AAK1 3017/4885LPL 2430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.